View source for Vaccine-preventable diseases

{| class="wikitable sortable"
! Disease
! Mode of transmission
! Incubation period (range)
! Infective period
! Basic reproductive number
! Vaccine name
! Type of vaccine
! Number and timing of doses
! Effectiveness
|-
| [[Diphtheria]]
| mode
| 2 to 5 days (1 to 10)
| up to 2 weeks (rarely 4 weeks, with very rare asymptomatic chronic shedders)
| 6 to 7
| Td, Tdap, DTaP, DTap-Hib-IPV
| toxoid
| 2, 4, 6, and 18 months; booster at 4 to 6 years and again ten years later
| 97 to 100% for at least 10 years
|-
| [[Haemophilus influenzae]] type b
| mode
| 2 to 4 days
| may be prolonged, until 24 hours after antibiotics
| 
| subunit conjugate
| type of vaccine
| 2, 4, 6, and 18 months
| 95 to 100%
|-
| [[Hepatitis B]]
| bloodborne and sexually-transmitted
| 60 to 90 days (24 to 180)
| 
| R0
| monovalent HB, or DTaP-HB-IPV-Hib
| subunit
| 2 to 3 doses; timing varies by province<br/>monovalent: 0, 1, and 6 months
| 95 to 100%
|-
| [[HPV]]
| contact
| 
| 
| 
| HPV2, HPV4, and HPV9
| recombinant subunit
| 0, 2, and 6 months (2 month dose optional if less than 15 years old)
| 100% for types covered; prevents 60 to 70% of anogenital and cervical cancers; lasts at least 10 years
|-
| [[Influenza]]
| droplet
| 2 days (1 to 4)
| 1 day before to 5 days after symptom onset
| 1.3 to 1.8
| IIV or LAIV
| inactivated or live attenuated
| 1 dose annually; 2 given 6 months apart if first time and under 9 years
| 40 to 60%
|-
| [[Measles]]
| airborne
| 8 to 12 days (7 to 21)
| 4 days before to 4 days after rash onset
| 12 to 18
| MMR or MMRV
| live attentuated
| 2 doses in childhood (12 months and 4 to 6 years) (as MMR/MMRV)
| 5% have waning immunity within a few years (hence the second dose)
|-
| [[Meningococcus]]
| droplet
| 3 to 4 days (2 to 10)
| 
| 
| Men-C-ACYW (± 4CMenB)
| conjugated subunit
| varies by province
| effectiveness
|-
| [[Mumps]]
| 
| 16 to 18 days (12 to 25)
| up to 5 days after onset of parotitis
| 4 to 7
| MMR or MMRV
| live attenuated
| 2 doses in childhood (12 months and 4 to 6 years) (as MMR/MMRV)
| 62% to 91% for 1 dose and 76% to 95% for 2 doses; may wane over years to decades
|-
| [[Pertussis]]
| droplet
| 9 to 10 days (6 to 20, rarely up to 42)
| greatest during catarrhal period and first 2 weeks after cough onset; no longer contagious after 5 days of antibiotics
| 12 to 17
| Tdap, DTaP, DTap-Hib-IPV
| toxoid
| 2, 4, 6, and 18 months; booster at 4 to 6 years and again 10 years later
| 90% for childhood pertussis, and 90% in pregnancy for protecting infants less than 3 months
|-
| [[Pneumococcus]]
| droplet
| unknown; as short as 1 to 3 days
| up to 24 hours following antibiotics
| 
| Pneu-C-20
| conjugate
| Pneu-C-20: 2, 4, and 12 months; or 2, 4, 6, and 12-15 months
| Pneu-C-13: 86 to 97% against included serotypes; Pneu-C-20: unknown
|-
| [[Polio]]
| fecal-oral
| 6 to 20 days (3 to 35)
| highest at disease onset, and up to 3 to 6 weeks
| 5 to 7
| DTaP-IPV-Hib or DTaP-HB-IPV-Hib (or OPV)
| killed (or live attenuated)
| 2, 4, 6, and 18 months
| 95%, up to 100% with an additional booster
|-
| [[Rotavirus]]
| fecal-oral
| 18 horus to 3 days
| from a few days before to 21 days after symptom onset
| 
| mono- or pentavalent
| live attenuated
| 2 (monovalent) or 3 (pentavalent) doses 4 weeks apart; complete between 6 weeks and 8 months of life
| 74 to 87%; 85 to 98% against severe diarrhea
|-
| [[Rubella]]
| droplet
| 14 to 17 days (14 to 21)
| 1 week before to 4 days after onset of rash (but up to age 1 year for CRS)
| 6 to 7
| MMR or MMRV
| live attenuated
| 1 dose needed, but usually given 2 doses at 12 months and 4 to 6 years as MMR/MMRV
| 95% with one dose; may wane in 10% of people over years to decades
|-
| [[Smallpox]]
| droplet or contact
| 10 to 14 days (7 to 19)
| highest in early disease, but infective from onset of rash until all scabs disappear (about 3 weeks)
| booster every 10 years if at risk
| lyphilized vaccinia
| live attenuated
| 
| 95%
|-
| [[Tetanus]]
| percutaneous inoculation
| 3 to 21 days (1 day to several months)
| no person-to-person transmission
| 
| Td, Tdap, DTaP, DTap-Hib-IPV
| toxoid
| 2, 4, 6, and 18 months; booster at 4 to 6 years and again 10 years later
| 99% but declines over time
|-
| [[Varicella]]
| airborne
| 14 to 16 days (10 to 21 days)
| 2 days before rash onset until all lesions crusted
| 
| MMRV or VZV
| live attenuated
| 12 months and again at 18 months to 6 years
| 85% with one dose, 98% with two doses (and 100% against severe disease)
|-
| [[Zoster]]
| contact
| 
| until all lesions crusted
| 
| Zostavax or Shingrix
| live attenuated or adjuvanted subunit
|
|
|}